ALDH1-High Ovarian Cancer Stem-Like Cells Can Be Isolated from Serous and Clear Cell Adenocarcinoma Cells, and ALDH1 High Expression Is Associated with Poor Prognosis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Kuroda, Takafumi ^a   Hirohashi, Yoshihiko ^a   Torigoe, Toshihiko ^a   Yasuda, Kazuyo ^a   Takahashi, Akari ^a   Asanuma, Hiroko ^a   Morita, Rena ^a   Mariya, Tasuku ^a   Asano, Takuya ^a   Mizuuchi, Masahito ^a   Saito, Tsuyoshi ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; KI 67 ANTIGEN; UNCLASSIFIED DRUG; ISOENZYME; RETINAL DEHYDROGENASE; TUMOR MARKER;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENICITY; CARCINOMA; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL INVASION; CELL ISOLATION; CELL POPULATION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PREDICTION; PROTEIN EXPRESSION; SEROUS CARCINOMA; TUMOR INVASION; ADENOCARCINOMA, CLEAR CELL; ANTIBODY SPECIFICITY; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PRIMARY CELL CULTURE; PROGNOSIS; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; PRIMARY CELL CULTURE; PROGNOSIS; RETINAL DEHYDROGENASE;

EID: 84878804228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065158     Document Type: Article

References (40)

1. Cho KR, Shih Ie M, (2009) Ovarian cancer. Annu Rev Pathol 4: 287-313.
2. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496.
3. Goff B, (2012) Symptoms associated with ovarian cancer. Clin Obstet Gynecol 55: 36-42.
4. Bast RC Jr, Hennessy B, Mills GB, (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
5. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106.
6. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, et al. (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
8. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
9. Hirohashi Y, Torigoe T, Inoda S, Morita R, Kochin V, et al. (2012) Cytotoxic T lymphocytes: Sniping cancer stem cells. Oncoimmunology 1: 123-125.
10. Dean M, Fojo T, Bates S, (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
11. Rich JN, (2007) Cancer stem cells in radiation resistance. Cancer Res 67: 8980-8984.
12. Hirohashi Y, Torigoe T, Inoda S, Takahashi A, Morita R, et al. (2010) Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy 2: 201-211.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
14. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
15. Zhang S, Balch C, Chan MW, Lai HC, Matei D, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
16. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, et al. (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148: 259-272.
17. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC, (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806.
18. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, et al. (2011) SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 91: 1796-1804.
19. Gangavarpu KJ, Huss WJ (2011) Isolation and applications of prostate side population cells based on dye cycle violet efflux. Curr Protoc Toxicol Chapter 22: Unit 22 22.
20. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
21. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389.
22. Nishida S, Hirohashi Y, Torigoe T, Kitamura H, Takahashi A, et al. (2012) Gene expression profiles of prostate cancer stem cells isolated by aldehyde dehydrogenase activity assay. J Urol 188: 294-299.
23. Deng S, Yang X, Lassus H, Liang S, Kaur S, et al. (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5: e10277.
24. Silva IA, Bai S, McLean K, Yang K, Griffith K, et al. (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71: 3991-4001.
25. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, et al. (2012) ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 180: 1159-1169.
26. Chang B, Liu G, Xue F, Rosen DG, Xiao L, et al. (2009) ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 22: 817-823.
27. Yabushita H, Ueno N, Sawaguchi K, Higuchi K, Noguchi M, et al. (1989) Establishment and characterization of a new human cell-line (AMOC-2) derived from a serous adenocarcinoma of ovary. Nihon Sanka Fujinka Gakkai Zasshi 41: 888-894.
28. Ishiwata I, Ishiwata C, Kobayashi N, Ishikawa H, (1987) Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. Nihon Sanka Fujinka Gakkai Zasshi 39: 831-836.
29. Kobayashi S, Yamada-Okabe H, Suzuki M, Natori O, Kato A, et al. (2012) LGR5-Positive Colon Cancer Stem Cells Interconvert with Drug Resistant LGR5-Negative Cells and are Capable of Tumor Reconstitution. Stem Cells.
30. Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, et al. (2012) Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. Mod Pathol.
31. Michifuri Y, Hirohashi Y, Torigoe T, Miyazaki A, Kobayashi J, et al. (2012) High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis. Pathol Int 62: 684-689.
32. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, et al. (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 103: 11154-11159.
33. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, et al. (2012) Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 7: e29079.
34. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, et al. (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27: 2875-2883.
35. Shi MF, Jiao J, Lu WG, Ye F, Ma D, et al. (2010) Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci 67: 3915-3925.
36. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH, (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29: 2672-2680.
37. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120.
38. Burkert J, Otto WR, Wright NA, (2008) Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol 214: 564-573.
39. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, et al. (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109: 370-376.
40. Miyamoto M, Takano M, Goto T, Kato M, Sasaki N, et al. (2013) Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review. J Gynecol Oncol 24: 37-43.